289483-81-4

Basic information

• Product Name: 4-methyl-7-nitro-1H-indole-3-carbaldehyde
• Synonyms: 4-methyl-7-nitro-1H-indole-3-carbaldehyde;4-methyl-7-nitro-1H-Indole-3-carboxaldehyde
• CAS NO: 289483-81-4
• Molecular Formula: C10H8N2O3
• Molecular Weight: 204.18212
• Mol File: 289483-81-4.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 4-methyl-7-nitro-1H-indole-3-carbaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 4-methyl-7-nitro-1H-indole-3-carbaldehyde(289483-81-4)
• EPA Substance Registry System: 4-methyl-7-nitro-1H-indole-3-carbaldehyde(289483-81-4)

Safety Data

• Hazardous Substances Data: 289483-81-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-methyl-7-nitro-1H-indole-3-carbaldehyde is used as a building block for the development of pharmaceuticals due to its unique structure and reactivity, which allows for the production of various compounds with biological and medicinal activities.
Used in Agrochemical Industry:
4-methyl-7-nitro-1H-indole-3-carbaldehyde is used as a building block in the development of agrochemicals, contributing to the creation of compounds with potential applications in agriculture.
Used in Dye Synthesis:
4-methyl-7-nitro-1H-indole-3-carbaldehyde is used as a starting material in the synthesis of dyes and other related organic compounds, thanks to the presence of the nitro group in its molecule.
Overall, 4-methyl-7-nitro-1H-indole-3-carbaldehyde is a valuable chemical in the field of organic chemistry and offers a wide range of applications in different industries.

Upstream product

• 289483-80-3 4-methyl-7-nitro-1H-indole 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 289483-82-5 3-Cyano-4-methyl-7-nitro-1H-indole 
• 289483-87-0 7-Amino-3-cyano-4-methyl-1H-indole 

Relevant articles and documents

SULFONAMIDE DERIVATIVES FOR PROTEIN DEGRADATION

DCAF15 is a substrate recognition (adaptor) protein of E3 ubiquitin ligase. Disclosed herein are compounds that recruit ubiquitin ligase CRL4DCAF15, to a target RNA recognition motif (RRM), causing its degradation. Also disclosed herein are compositions and methods of use in treating associated disorders and diseases.

Process for preparing sulfonamide-containing indole compounds

A process for preparing a compound (5a) represented by the following formula: wherein R1 and R2 each independently represent hydrogen, C1-4 alkyl, etc. and A represents cyanophenyl, etc., characterized by reacting a compou

Integrin expression inhibitors

The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them. In the formula, B means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated; K means a single bond, —CH═CH— or —(CR4bR5b)mb— (wherein R4b and R5b are the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group; and mb means an integer of 1 or 2); R1 means hydrogen atom or a C1-C6 alkyl group; Z means a single bond or —CO—NH—; and R means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated, respectively.

Sulfonamide-containing indole compounds

The present invention creates a novel antiangiogenic agent and provides an antitumor agent which shows high safety as compared with conventional antitumor agents, has a sure effect and is able to be administered for a long period. That is, it provides an indole compound represented by the following formula (I), its pharmacologically acceptable salt or hydrates thereof. In the formula, R1 represents hydrogen atom, a halogen atom or cyano group; R2 and R3 are the same as or different from and each represents hydrogen atom, a C1-C4 lower alkyl group or a halogen atom; R4 represents hydrogen atom or a C1-C4 lower alkyl group; and the ring A represents cyanophenyl group, aminosulfonylphenyl group, aminopyridyl group, aminopyrimidyl group, a halopyridyl group or cyanothiophenyl group, provided that the case where all of R1, R2 and R3 are hydrogen atoms, where both R2 and R3 are hydrogen atoms or where the ring A is aminosulfonyl group and both R1 and R2 are halogen atoms is excluded. Further, when the ring A is cyanophenyl group, 2-amino-5-pyridyl group or a 2-halo-5-pyridyl group and R1 is cyano group or a halogen atom, at least one of R2 and R3 should not be a hydrogen atom.

INTEGRIN EXPRESSION INHIBITORS

The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them. In the formula, B means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated; K means a single bond, -CH=CH- or - (CR4bR5b)mb- (wherein R4b and R5b are the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group; and mb means an integer of 1 or 2); R1 means hydrogen atom or a C1-C6 alkyl group; Z means a single bond or -CO-NH-; and R means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated, respectively.